CyberKnife Sales Key for Accuray

Accuray, Inc. (Nasdaq: ARAY) has developed the first and only commercially available intelligent robotic radiosurgery system, the CyberKnife System, designed to treat solid tumors anywhere in the body as an alternative to traditional surgery. However, although the company believes that the System has advantages over competing products and technologies, it does not have sufficient clinical data demonstrating the advantages for all tumor indications.

Accuray's technology and system have the necessary competitive advantages over traditional treatment methods and it has been driving significantly higher revenue from the successful execution of its growth strategy. The company's ability to achieve and maintain long-term profitability is largely dependent on its ability to successfully market and sell the CyberKnife System, control costs and effectively manage growth.

NETC a Quality Brazilian Play

We are reiterating our Buy recommendation on Net Servicos (Nasdaq: NETC). Although higher worldwide inflation and interest rates, particularly in Brazil, are source of great concern, we are highly encouraged by the company's solid operating results during the first quarter. We expect this trend to continue in the short term due to the still positive economic environment in Brazil.

Brazil was recently upgraded to investment grade by Standard & Poor's and by Fitch. The outlook for Brazilian real in the short term remains positive, and that will help reduce the interest expenses in the following quarters. The incorporation of Vivax and BIGTV consolidates the company's presence in the key State of Sao Paulo. Additionally, the performance of its voice service and broadband products remains highly encouraging.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/ ?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http:/ /at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

(c) 2008 BUSINESS WIRE. Provided by ProQuest Information and Learning. All rights Reserved.

Story Source: BUSINESS WIRE